U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07723066) titled 'Biomarker Discovery for Suicide Precision Circuit Therapeutics' on July 20.
Brief Summary: This is a prospective observational biomarker study assessing changes in clinical, behavioral, neuroimaging, and neurophysiological measurer following ketamine/esketamine or electroconvulsive therapy (ECT) in adults with suicidal thoughts or behaviors.
Study Start Date: July, 2026
Study Type: OBSERVATIONAL
Condition:
Suicidal Thoughts and Behaviors
Major Depressive Episode (MDE)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Massachusetts General Hospital
Information provided by (Responsible Party): Joan A Camprodon, MD MPH PhD, Massac...